Minzhi Xing MD, Presenter: Nothing to Disclose

Nima Kokabi MD, Abstract Co-Author: Nothing to Disclose

Hyun Sik Kim MD, Abstract Co-Author: Nothing to Disclose

To evaluate the effects of age on survival outcomes in patients with advanced unresectable hepatocellular carcinoma (HCC) treated with Drug-Eluting Bead Chemoembolization (DEB-TACE) or best supportive care in a large-scale population study.

Under IRB approval, our institute’s cancer registry was queried for patients with advanced unresectable HCC diagnosed from Sept 2005 to Dec 2010, treated with DEB-TACE. Eighteen registries of the U.S. Surveillance, Epidemiology and End Results (SEER) database were queried for patients with advanced HCC not amenable to surgery/radiation diagnosed in the same time period. Baseline characteristics, median overall survival (OS) from HCC diagnosis and median OS from first DEB-TACE were stratified by age at HCC diagnosis. Survival analysis and 95% confidence intervals (CI) were calculated using Kaplan-Meier estimation.

A total of 20,897 SEER patients with unresectable HCC who received neither radiation nor cancer-directed surgery and 231 patients who received DEB-TACE for advanced unresectable HCC were included. Of these, 11649 SEER patients and 155 DEB-TACE patients were <65 years of age at HCC diagnosis, compared with 9248 SEER and 76 DEB-TACE patients who were ≥65 years at diagnosis. All groups were similar for gender, race, bilobar disease, portal vein thrombosis, and mean largest tumor size (p>0.05). Median OS in patients <65 years was similar to patients ≥65 years at HCC diagnosis (4.1 vs. 4.0 months, p>0.05). Significant differences in median OS from HCC diagnosis between groups were observed in patients <65 years at diagnosis (SEER vs. DEB-TACE, 4.0 vs. 23.47 months, p<0.0001) and ≥65 years at diagnosis (SEER vs. DEB-TACE, 4.0 vs. 21.1 months, p<0.0001).

In a population-based study, DEB-TACE therapy in patients with advanced, unresectable HCC demonstrated significantly greater median OS compared to best supportive care regardless of age at diagnosis.

Regardless of age at HCC diagnosis, DEB-TACE therapy in patients with advanced, unresectable HCC demonstrates significant survival benefit vs. best supportive care.

Xing, M, Kokabi, N, Kim, H, The Effect of Age on Survival Outcomes in Unresectable Hepatocellular Carcinoma Treated with DEB-TACE: Surveillance, Epidemiology and End Results (SEER) Database vs. Tertiary Cancer Center.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14019592.html